Tepotinib is from which country?

Tepotinib is a once-daily oral MET inhibitor that inhibits oncogenic MET receptor signaling caused by changes in the MET (gene). Tepotinib was discovered and developed by Merck & Co. (Merck). It has a highly selective mechanism of action and has the potential to improve the prognosis of aggressive tumors with poor prognosis and these specific changes.

Tepotinib was first approved in Japan in March 2020. In February 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval of tepotinib, making it the first and only once-daily oral MET inhibitor approved for use in U.S. patients with metastatic non-small cell lung cancer, with a METex14-skipping change. In February 2022, the European Commission (EC) approved once-daily oral tepotinib as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer harboring alterations leading to mesenchymal-epithelial transformation factor gene exon 14 (METex14) skipping who require systemic therapy after treatment with immunotherapy and/or platinum-based chemotherapy.

The original drug Tepotinib is already on the market in China, but it is not yet eligible for medical insurance. Tepotinib Original drug currently marketed overseas is relatively expensive, and the price of each box of 225mg*30 tablets may be around RMB 80,000 (the price may fluctuate due to exchange rates). There are already generic Tepotinib drugs produced in other countries. The ingredients of these generic drugs are basically the same as those of the original drug, but the price is relatively cheap. For example, the price of 225mg*60 tablets produced by a Laos pharmaceutical factory may be more than 8,000 yuan per box (the price may fluctuate due to exchange rates).